Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Emisphere Appoints New Chief Financial Officer and New Director of Research
Emisphere Appoints New Chief Financial Officer and New Director of Research Tarrytown, NY, April 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Charles H. Abdalian, Jr. has joined the Company as Chief Financial Officer, a newly created position, and that Steven M.
View HTML
Toggle Summary Emisphere Reports 1999 Second Quarter and Six Month Financial Results
Emisphere Reports 1999 Second Quarter and Six Month Financial Results Tarrytown, NY and Dublin, Ireland, March 17, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported financial results for the second quarter and six months ended January 31, 1999.
View HTML
Toggle Summary Emisphere Announces Update on Oral Heparin Development Program
Emisphere Announces Update on Oral Heparin Development Program Tarrytown, NY, February 25, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported on a number of key events in their oral heparin program. First, the manufacturing process for the Emisphere carrier has been successfully
View HTML
Toggle Summary Emisphere Announces Spinout of a New Drug Development Company
Emisphere Announces Spinout of a New Drug Development Company Tarrytown, NY and Dublin, Ireland, January 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will form a new subsidiary company to explore the development of a novel drug design technology.
View HTML
Toggle Summary Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product
Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product Hawthorne, NY and Dublin, Ireland, January 11, 1999 --- Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) and Elan Corporation, plc (NYSE: ELN) announced that the preliminary results of the Phase II oral
View HTML
Toggle Summary Emisphere Reports 1998 Fourth Quarter and Year End Financial Results
Emisphere Reports 1998 Fourth Quarter and Year End Financial Results Hawthorne, NY, October 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported fourth quarter and year end financial results for the period ended July 31, 1998. Net loss for the fourth quarter of 1998 was $3.4
View HTML
Toggle Summary Lilly and Emisphere Announce Osteoporosis Compound to Enter Clinical Trials
Lilly and Emisphere Announce Osteoporosis Compound to Enter Clinical Trials Indianapolis, IN, and Tarrytown, NY September 3, 1998 --- Eli Lilly & Co. (NYSE: LLY) and Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) announced today that Lilly has formally selected a proprietary Emisphere carrier for
View HTML
Toggle Summary Emisphere and Elan Contribute $10 Million to Heparin Joint Venture
Emisphere and Elan Contribute $10 Million to Heparin Joint Venture Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral
View HTML
Toggle Summary Emisphere Reports 1998 Third Quarter and Nine Month Financial Results
Elan Makes Additional $4 Million Investment in Emisphere Through Warrant Exercise
View HTML
Toggle Summary Emisphere Announces Initiation of Phase II Clinical Trial for Oral Heparin Product
Emisphere Announces Initiation of Phase II Clinical Trial for Oral Heparin Product Hawthorne, NY, May 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today it has initiated a Phase II clinical study for its oral heparin product for the prevention of deep vein thrombosis.
View HTML
Toggle Summary Emisphere Announces New Senior Vice President of Clinical Affairs
Emisphere Announces New Senior Vice President of Clinical Affairs Hawthorne, NY, May 20, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Barry B. Kanarek, M.D., Ph.D., has joined the Company as Senior Vice President of Clinical Affairs, a newly created position. Dr.
View HTML
Toggle Summary Emisphere Announces $13.5 Million Private Placement
Emisphere Announces $13.5 Million Private Placement Hawthorne, NY, May 4, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the closing of a $13.5 million private placement of 5% senior convertible notes. Emisphere plans to use the proceeds of the private placement for general
View HTML
Toggle Summary Emisphere Reports 1998 Second Quarter and Six Month Financial Results
Emisphere Reports 1998 Second Quarter and Six Month Financial Results Hawthorne, NY, March 19, 1998 --- Emisphere Technologies, Inc. (Nasdaq: NMS:EMIS) today reported a net loss of approximately $2.6 million, or $0.25 per share, for the second quarter ended January 31, 1998, as compared to net loss
View HTML
Toggle Summary Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements
Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements Hawthorne, NY and Indianapolis IN, March 16, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) and Eli Lilly & Co. (NYSE:LLY) announced today that Lilly has executed two license agreements with
View HTML
Toggle Summary Emisphere and Elan Announce Successful Completion of Additional Clinical Trials for Oral Heparin Preparation; Joint Venture Will Also Develop Oral Low Molecular Weight Heparin Product
Elan Makes Additional $4 Million Investment in Emisphere Through Warrant Exercise
View HTML

FOLLOW US